A Phase 1 Study in Subjects with Relapsed or Refractory Multiple Myeloma

- Pathologically documented,multiple myeloma relapsed or refractory progressive disease after at least 3 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g. bortezomib) and immunomodulatory drugs (e.g. lenalidomide). - Willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines). - Measurable disease per the International Myeloma Working Group (IMWG) response criteria - Hematological function, as follows, without transfusion support: - Absolute neutrophil count ≥ 1.0 X 10^9/L, - Platelet count ≥ 75 X 10^9/L (in patients with < 50% of bone marrow nucleated cells were plasma cells) or ≥ 50 X 10^9/L (in patients with ≥ 50% of bone marrow nucleated cells were plasma cells) without transfusion or growth factor support - Hemoglobin > 8 g/dL (> 80 g/L) - Adequate renal and hepatic function - Left ventricular ejection fraction (LVEF) > 50%

- Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study - Autologous stem cell transplant less than 90 days prior to study day 1 - Multiple myeloma with IgM subtype - POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, Plasma cell leukemia, Waldenstrom’s macroglobulinemia or Amyloidosis - Glucocorticoid therapy (prednisone > 30 mg/day or equivalent) within 7 days prior to study day - Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II) - A baseline ECG QTcF > 470 msec - Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1